2022 American Transplant Congress
Renal Function at Five Years from a Randomized Multicenter Trial of Belatacept-Based CNI Free and Early Steroid Withdrawal Immunosuppression
1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH
*Purpose: BENEFIT and BENEFIT EXT trials have demonstrated that belatacept-based immunosuppression was associated with improved long term renal allograft function compared to cyclosporine-based immunosuppression. Similar…2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…2022 American Transplant Congress
Tolerant B Cells Suppress Memory B Cells in a Donor Specific Manner in CoB Mediated Transplantation Tolerance
*Purpose: We previously reported that B cells in recipients made tolerant to fully mismatched heart allografts by anti-CD154+donor spleen cells (CoB) become dysfunctional in their…2022 American Transplant Congress
Donor-Specificb Cell Dysfunction and Suppressive Ability Are Differentially Induced in Cob-Mediated Transplantation Tolerance
*Purpose: B cells in mice tolerized to fully mismatched heart allografts with anti-CD154+donor spleen cells (CoB) are intrinsically dysfunctional and unable to differentiate into germinal…2022 American Transplant Congress
Belatacept Augments Mixed Chimerism in a Novel Nonhuman Primate Kidney Transplant Tolerance Induction Protocol
University of Wisconsin, Madison, WI
*Purpose: A novel protocol of antilymphocyte globulin (ATG), tomotherapy-based total lymphoid irradiation (TomoTLI), and adoptive cellular transfer was developed in a preclinical model of MHC-mismatched…2022 American Transplant Congress
Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens
1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH
*Purpose: A prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based, calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a tacrolimus (TAC)-based ESW…2022 American Transplant Congress
Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
*Purpose: The iBox is a prognostication system for long-term kidney allograft survival, developed with mostly patients under a CNI based immunosuppression. Patients treated with a…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation
Department of Pathology, Johns Hopkins University, Baltimore, MD
*Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due…2022 American Transplant Congress
Conversion to Belatacept for Calcineurin Inhibitor Toxicities
Columbia University Medical Center, New York, NY
*Purpose: Calcineurin inhibitors (CNIs) have improved renal transplant (RTx) outcomes but are associated with significant toxicities. Belatacept provides better long-term outcomes than cyclosporine, has less…
- 1
- 2
- 3
- …
- 30
- Next Page »